Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large decline in short interest in August. As of August 14th, there was short interest totaling 187 shares, a decline of 86.5% from the July 30th total of 1,385 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 1,011 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Molecular Partners stock. SmartHarvest Portfolios LLC lifted its position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) by 26.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,543 shares of the company’s stock after purchasing an additional 3,232 shares during the quarter. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 as of its most recent SEC filing. 26.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MOLN has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Wednesday, July 8th. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Price Performance

NASDAQ:MOLN traded down $0.15 during mid-day trading on Friday, hitting $4.50. The company’s stock had a trading volume of 1,551 shares, compared to its average volume of 4,803. The business’s fifty day moving average is $4.06 and its two-hundred day moving average is $4.23. The stock has a market cap of $181.69 million, a price-to-earnings ratio of -2.63 and a beta of 1.08. Molecular Partners has a 1 year low of $3.53 and a 1 year high of $5.36.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Tuesday, August 25th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. Analysts anticipate that Molecular Partners will post -1.28 EPS for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.